Viibryd (VI-brid) marketed as a new "dual-acting" serotonergic antidepressant

You'll see Viibryd (VI-brid) marketed as a new "dual-acting" serotonergic antidepressant.

Viibryd (vilazodone) inhibits serotonin reuptake like it's also a partial serotonin agonist.

The company hoped Viibryd would be more effective than SSRIs.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote